We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $88 · 5 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Corcept Therapeutics (CORT) Is Up 15.4% After Positive Lifyorli Phase 3 Ovarian Cancer Survival Data – Has The Bull Case Changed? - simplywall.st
Corcept Therapeutics (CORT) Is Up 15.4% After Positive Lifyorli Phase 3 Ovarian Cancer Survival Data – Has The Bull Case Changed? simplywall.st
Corcept Therapeutics Stock On Fire: Up 26% With 8-Day Winning Streak - Trefis
Corcept Therapeutics Stock On Fire: Up 26% With 8-Day Winning Streak Trefis
Corcept Therapeutics Stock On Fire: Up 26% With 8-Day Winning Streak - Trefis
Corcept Therapeutics Stock On Fire: Up 26% With 8-Day Winning Streak Trefis
Corcept Therapeutics chief accounting officer sells $325,000 in stock - Investing.com
Corcept Therapeutics chief accounting officer sells $325,000 in stock Investing.com
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $0.04 | — | — | $222.2M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.17 | — | — | $157.21M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.98 | — | — | $493.15M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.57 | — | — | $310.6M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 29. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 28. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 13. | UBS | — | Upgrade | Neutral → Buy | — | UBS: Neutral → Buy |
| 2026. 05. 04. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 02. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 03. 27. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 945,884 | $38.13B | 0.03% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 56,181 | $2.26B | 0.00% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 27,959 | $972.97M | 0.00% | — | New position |